A股異動丨恩捷股份(002812.SZ)漲逾5% 與寧德時代80億合建幹法及濕法隔離膜項目
格隆匯11月11日丨恩捷股份(002812.SZ)高開高走,現漲逾5%,報278元,總市值2481億元。恩捷股份公吿稱,將與寧德時代開展合作,雙方約定於中國境內共同投資設立一家平台公司,主要從事投資幹法隔離膜及濕法隔離膜項目。新公司的總投資額為80億元,註冊資本為15億元。恩捷股份先出資7.65億元設立平台公司,在滿足協議約定的先決條件後,寧德時代對平台公司增資7.35億元。增資完成後,恩捷股份持有平台公司51%股權,寧德時代持有平台公司49%股權。新平台公司的註冊地為浙江省寧波市梅山保税港區,最終名稱尚未確定,初步規劃幹法隔離膜及濕法隔離膜產能16億平/年。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.